Browse PTAFR

Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol-calcium second messenger system.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002283 neutrophil activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002691 regulation of cellular extravasation
GO:0002693 positive regulation of cellular extravasation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002888 positive regulation of myeloid leukocyte mediated immunity
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006066 alcohol metabolic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006417 regulation of translation
GO:0006820 anion transport
GO:0006821 chloride transport
GO:0006887 exocytosis
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006939 smooth muscle contraction
GO:0006940 regulation of smooth muscle contraction
GO:0007159 leukocyte cell-cell adhesion
GO:0007567 parturition
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009608 response to symbiont
GO:0009609 response to symbiotic bacterium
GO:0009629 response to gravity
GO:0010359 regulation of anion channel activity
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010608 posttranscriptional regulation of gene expression
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010676 positive regulation of cellular carbohydrate metabolic process
GO:0010863 positive regulation of phospholipase C activity
GO:0010919 regulation of inositol phosphate biosynthetic process
GO:0014074 response to purine-containing compound
GO:0014831 gastro-intestinal system smooth muscle contraction
GO:0015698 inorganic anion transport
GO:0016051 carbohydrate biosynthetic process
GO:0017157 regulation of exocytosis
GO:0019229 regulation of vasoconstriction
GO:0019233 sensory perception of pain
GO:0019751 polyol metabolic process
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022898 regulation of transmembrane transporter activity
GO:0030335 positive regulation of cell migration
GO:0031644 regulation of neurological system process
GO:0031646 positive regulation of neurological system process
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0031960 response to corticosteroid
GO:0032409 regulation of transporter activity
GO:0032411 positive regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032414 positive regulation of ion transmembrane transporter activity
GO:0032496 response to lipopolysaccharide
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032755 positive regulation of interleukin-6 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032957 inositol trisphosphate metabolic process
GO:0032958 inositol phosphate biosynthetic process
GO:0032959 inositol trisphosphate biosynthetic process
GO:0033002 muscle cell proliferation
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034341 response to interferon-gamma
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035150 regulation of tube size
GO:0035587 purinergic receptor signaling pathway
GO:0035588 G-protein coupled purinergic receptor signaling pathway
GO:0035589 G-protein coupled purinergic nucleotide receptor signaling pathway
GO:0035590 purinergic nucleotide receptor signaling pathway
GO:0036230 granulocyte activation
GO:0040017 positive regulation of locomotion
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042119 neutrophil activation
GO:0042226 interleukin-6 biosynthetic process
GO:0042310 vasoconstriction
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043270 positive regulation of ion transport
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043302 positive regulation of leukocyte degranulation
GO:0043312 neutrophil degranulation
GO:0043313 regulation of neutrophil degranulation
GO:0043315 positive regulation of neutrophil degranulation
GO:0043647 inositol phosphate metabolic process
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0044057 regulation of system process
GO:0044070 regulation of anion transport
GO:0044262 cellular carbohydrate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0044706 multi-multicellular organism process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045055 regulated exocytosis
GO:0045056 transcytosis
GO:0045123 cellular extravasation
GO:0045408 regulation of interleukin-6 biosynthetic process
GO:0045410 positive regulation of interleukin-6 biosynthetic process
GO:0045727 positive regulation of translation
GO:0045776 negative regulation of blood pressure
GO:0045785 positive regulation of cell adhesion
GO:0045907 positive regulation of vasoconstriction
GO:0045909 positive regulation of vasodilation
GO:0045913 positive regulation of carbohydrate metabolic process
GO:0045921 positive regulation of exocytosis
GO:0045933 positive regulation of muscle contraction
GO:0045987 positive regulation of smooth muscle contraction
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046683 response to organophosphorus
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048545 response to steroid hormone
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050880 regulation of blood vessel size
GO:0050900 leukocyte migration
GO:0050901 leukocyte tethering or rolling
GO:0051047 positive regulation of secretion
GO:0051272 positive regulation of cellular component movement
GO:0051384 response to glucocorticoid
GO:0051591 response to cAMP
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0060137 maternal process involved in parturition
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060359 response to ammonium ion
GO:0060627 regulation of vesicle-mediated transport
GO:0060732 positive regulation of inositol phosphate biosynthetic process
GO:0061756 leukocyte adhesion to vascular endothelial cell
GO:0070542 response to fatty acid
GO:0071214 cellular response to abiotic stimulus
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071229 cellular response to acid chemical
GO:0071242 cellular response to ammonium ion
GO:0071258 cellular response to gravity
GO:0071320 cellular response to cAMP
GO:0071346 cellular response to interferon-gamma
GO:0071396 cellular response to lipid
GO:0071398 cellular response to fatty acid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071548 response to dexamethasone
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0090066 regulation of anatomical structure size
GO:0090257 regulation of muscle system process
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1900274 regulation of phospholipase C activity
GO:1901529 positive regulation of anion channel activity
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1901654 response to ketone
GO:1902563 regulation of neutrophil activation
GO:1902565 positive regulation of neutrophil activation
GO:1902930 regulation of alcohol biosynthetic process
GO:1902932 positive regulation of alcohol biosynthetic process
GO:1902941 regulation of voltage-gated chloride channel activity
GO:1902943 positive regulation of voltage-gated chloride channel activity
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903236 regulation of leukocyte tethering or rolling
GO:1903238 positive regulation of leukocyte tethering or rolling
GO:1903305 regulation of regulated secretory pathway
GO:1903307 positive regulation of regulated secretory pathway
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903532 positive regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903793 positive regulation of anion transport
GO:1903795 regulation of inorganic anion transmembrane transport
GO:1903797 positive regulation of inorganic anion transmembrane transport
GO:1903959 regulation of anion transmembrane transport
GO:1903961 positive regulation of anion transmembrane transport
GO:1904058 positive regulation of sensory perception of pain
GO:1904298 regulation of transcytosis
GO:1904300 positive regulation of transcytosis
GO:1904301 regulation of maternal process involved in parturition
GO:1904303 positive regulation of maternal process involved in parturition
GO:1904304 regulation of gastro-intestinal system smooth muscle contraction
GO:1904306 positive regulation of gastro-intestinal system smooth muscle contraction
GO:1904316 response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine
GO:1904317 cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine
GO:1904994 regulation of leukocyte adhesion to vascular endothelial cell
GO:1904996 positive regulation of leukocyte adhesion to vascular endothelial cell
GO:2000147 positive regulation of cell motility
GO:2000241 regulation of reproductive process
GO:2000243 positive regulation of reproductive process
GO:2001225 regulation of chloride transport
Molecular Function GO:0001530 lipopolysaccharide binding
GO:0001608 G-protein coupled nucleotide receptor activity
GO:0001614 purinergic nucleotide receptor activity
GO:0001875 lipopolysaccharide receptor activity
GO:0004992 platelet activating factor receptor activity
GO:0005543 phospholipid binding
GO:0008329 signaling pattern recognition receptor activity
GO:0016502 nucleotide receptor activity
GO:0035586 purinergic receptor activity
GO:0038187 pattern recognition receptor activity
GO:0045028 G-protein coupled purinergic nucleotide receptor activity
GO:0051019 mitogen-activated protein kinase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6798695: Neutrophil degranulation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTAFR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTAFR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18483284Skin CarcinomaInhibit immunityEarly steps in the cascade of events leading to immune suppression are the binding of UV-induced platelet-activating factor (PAF) to its receptor and the binding of cis-urocanic acid, a photoreceptor for UVB radiation, to the serotonin (5-HT(2A)) receptor. These data indicate that treating UV-irradiated mice with PAF and 5-HT(2A) receptor antagonists blocks skin cancer induction in vivo, in part by reversing UV-induced damage to the skin and by preventing the induction of immune suppression.
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTAFR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTAFR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0390.924
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0910.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0030.997
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.090.857
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6170.614
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9870.536
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3870.436
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6050.65
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1020.947
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2120.351
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4170.479
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2140.109
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTAFR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTAFR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTAFR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTAFR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTAFR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTAFR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTAFR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTAFR
Nameplatelet-activating factor receptor
Aliases PAF-R
Chromosomal Location1p35-p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTAFR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PTAFR.
ID Name Drug Type Targets #Targets
DB02261Platelet Activating FactorSmall MoleculeGM2A, PTAFR2
DB09166EtizolamSmall MoleculeGABRA1, GABRA2, GABRA3, GABRG2, PTAFR5
DB11614RupatadineSmall MoleculeHRH1, PTAFR2